These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
293 related articles for article (PubMed ID: 27662658)
1. Synergistic activity of ALK and mTOR inhibitors for the treatment of NPM-ALK positive lymphoma. Redaelli S; Ceccon M; Antolini L; Rigolio R; Pirola A; Peronaci M; Gambacorti-Passerini C; Mologni L Oncotarget; 2016 Nov; 7(45):72886-72897. PubMed ID: 27662658 [TBL] [Abstract][Full Text] [Related]
2. Activating mutations in ALK kinase domain confer resistance to structurally unrelated ALK inhibitors in NPM-ALK-positive anaplastic large-cell lymphoma. Zdzalik D; Dymek B; Grygielewicz P; Gunerka P; Bujak A; Lamparska-Przybysz M; Wieczorek M; Dzwonek K J Cancer Res Clin Oncol; 2014 Apr; 140(4):589-98. PubMed ID: 24509625 [TBL] [Abstract][Full Text] [Related]
3. Crizotinib in Combination with Everolimus Synergistically Inhibits Proliferation of Anaplastic Lymphoma Kinase‒Positive Anaplastic Large Cell Lymphoma. Xu W; Kim JW; Jung WJ; Koh Y; Yoon SS Cancer Res Treat; 2018 Apr; 50(2):599-613. PubMed ID: 28675026 [TBL] [Abstract][Full Text] [Related]
4. Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma. Christensen JG; Zou HY; Arango ME; Li Q; Lee JH; McDonnell SR; Yamazaki S; Alton GR; Mroczkowski B; Los G Mol Cancer Ther; 2007 Dec; 6(12 Pt 1):3314-22. PubMed ID: 18089725 [TBL] [Abstract][Full Text] [Related]
5. Prognostic significance and therapeutic potential of the activation of anaplastic lymphoma kinase/protein kinase B/mammalian target of rapamycin signaling pathway in anaplastic large cell lymphoma. Gao J; Yin M; Zhu Y; Gu L; Zhang Y; Li Q; Jia C; Ma Z BMC Cancer; 2013 Oct; 13():471. PubMed ID: 24112608 [TBL] [Abstract][Full Text] [Related]
6. Activation of mammalian target of rapamycin signaling pathway contributes to tumor cell survival in anaplastic lymphoma kinase-positive anaplastic large cell lymphoma. Vega F; Medeiros LJ; Leventaki V; Atwell C; Cho-Vega JH; Tian L; Claret FX; Rassidakis GZ Cancer Res; 2006 Jul; 66(13):6589-97. PubMed ID: 16818631 [TBL] [Abstract][Full Text] [Related]
7. Targeting autophagy enhances the anti-tumoral action of crizotinib in ALK-positive anaplastic large cell lymphoma. Mitou G; Frentzel J; Desquesnes A; Le Gonidec S; AlSaati T; Beau I; Lamant L; Meggetto F; Espinos E; Codogno P; Brousset P; Giuriato S Oncotarget; 2015 Oct; 6(30):30149-64. PubMed ID: 26338968 [TBL] [Abstract][Full Text] [Related]
8. Activation of IGF-1R pathway and NPM-ALK G1269A mutation confer resistance to crizotinib treatment in NPM-ALK positive lymphoma. Li Y; Wang K; Song N; Hou K; Che X; Zhou Y; Liu Y; Zhang J Invest New Drugs; 2020 Jun; 38(3):599-609. PubMed ID: 31177400 [TBL] [Abstract][Full Text] [Related]
9. Molecular rationale for the use of PI3K/AKT/mTOR pathway inhibitors in combination with crizotinib in ALK-mutated neuroblastoma. Moore NF; Azarova AM; Bhatnagar N; Ross KN; Drake LE; Frumm S; Liu QS; Christie AL; Sanda T; Chesler L; Kung AL; Gray NS; Stegmaier K; George RE Oncotarget; 2014 Sep; 5(18):8737-49. PubMed ID: 25228590 [TBL] [Abstract][Full Text] [Related]
10. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors. Ceccon M; Mologni L; Bisson W; Scapozza L; Gambacorti-Passerini C Mol Cancer Res; 2013 Feb; 11(2):122-32. PubMed ID: 23239810 [TBL] [Abstract][Full Text] [Related]
11. The second-generation ALK inhibitor alectinib effectively induces apoptosis in human neuroblastoma cells and inhibits tumor growth in a TH-MYCN transgenic neuroblastoma mouse model. Lu J; Guan S; Zhao Y; Yu Y; Woodfield SE; Zhang H; Yang KL; Bieerkehazhi S; Qi L; Li X; Gu J; Xu X; Jin J; Muscal JA; Yang T; Xu GT; Yang J Cancer Lett; 2017 Aug; 400():61-68. PubMed ID: 28455243 [TBL] [Abstract][Full Text] [Related]
12. Antitumor activity of pimasertib, a selective MEK 1/2 inhibitor, in combination with PI3K/mTOR inhibitors or with multi-targeted kinase inhibitors in pimasertib-resistant human lung and colorectal cancer cells. Martinelli E; Troiani T; D'Aiuto E; Morgillo F; Vitagliano D; Capasso A; Costantino S; Ciuffreda LP; Merolla F; Vecchione L; De Vriendt V; Tejpar S; Nappi A; Sforza V; Martini G; Berrino L; De Palma R; Ciardiello F Int J Cancer; 2013 Nov; 133(9):2089-101. PubMed ID: 23629727 [TBL] [Abstract][Full Text] [Related]
13. New therapeutic strategies in neuroblastoma: combined targeting of a novel tyrosine kinase inhibitor and liposomal siRNAs against ALK. Di Paolo D; Yang D; Pastorino F; Emionite L; Cilli M; Daga A; Destafanis E; Di Fiore A; Piaggio F; Brignole C; Xu X; Liang C; Gibbons J; Ponzoni M; Perri P Oncotarget; 2015 Oct; 6(30):28774-89. PubMed ID: 26299615 [TBL] [Abstract][Full Text] [Related]
14. Crizotinib enhances anti-CD30-LDM induced antitumor efficacy in NPM-ALK positive anaplastic large cell lymphoma. Wang R; Li L; Duan A; Li Y; Liu X; Miao Q; Gong J; Zhen Y Cancer Lett; 2019 Apr; 448():84-93. PubMed ID: 30742941 [TBL] [Abstract][Full Text] [Related]
15. Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway. Marzec M; Kasprzycka M; Liu X; El-Salem M; Halasa K; Raghunath PN; Bucki R; Wlodarski P; Wasik MA Oncogene; 2007 Aug; 26(38):5606-14. PubMed ID: 17353907 [TBL] [Abstract][Full Text] [Related]
16. NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922. Mologni L; Ceccon M; Pirola A; Chiriano G; Piazza R; Scapozza L; Gambacorti-Passerini C Oncotarget; 2015 Mar; 6(8):5720-34. PubMed ID: 25749034 [TBL] [Abstract][Full Text] [Related]
17. CEP-28122, a highly potent and selective orally active inhibitor of anaplastic lymphoma kinase with antitumor activity in experimental models of human cancers. Cheng M; Quail MR; Gingrich DE; Ott GR; Lu L; Wan W; Albom MS; Angeles TS; Aimone LD; Cristofani F; Machiorlatti R; Abele C; Ator MA; Dorsey BD; Inghirami G; Ruggeri BA Mol Cancer Ther; 2012 Mar; 11(3):670-9. PubMed ID: 22203728 [TBL] [Abstract][Full Text] [Related]
18. Therapeutic efficacy of the bromodomain inhibitor OTX015/MK-8628 in ALK-positive anaplastic large cell lymphoma: an alternative modality to overcome resistant phenotypes. Boi M; Todaro M; Vurchio V; Yang SN; Moon J; Kwee I; Rinaldi A; Pan H; Crescenzo R; Cheng M; Cerchietti L; Elemento O; Riveiro ME; Cvitkovic E; Bertoni F; Inghirami G; Oncotarget; 2016 Nov; 7(48):79637-79653. PubMed ID: 27793034 [TBL] [Abstract][Full Text] [Related]
19. Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK. Fontana D; Ceccon M; Gambacorti-Passerini C; Mologni L Cancer Med; 2015 Jul; 4(7):953-65. PubMed ID: 25727400 [TBL] [Abstract][Full Text] [Related]
20. [Blockage of mTOR signaling pathway by rapamycin contributes to inhibition of tumor cell proliferation in ALK-positive lymphoid cell strains]. Gu L; Li JF; Gao J; Zhu YP; Li Q; Jia CS; Zhou CY; Ma ZG Zhonghua Xue Ye Xue Za Zhi; 2008 Oct; 29(10):662-6. PubMed ID: 19176057 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]